T&L Co (340570) Fair Value & Analysis
Healthcare · KR · Market cap 409B KRW
Fair value as of: Jul 22, 2026
From 24 valuation models · updated 18 days ago
Fair value updated Jul 22, 2026, revised from 97,873 KRW to 98,276 KRW (+0.4%) since Jun 25, 2026. Share price −36.9% over the past month.
A solid business, screening 195% undervalued on our models.
What matters now
- The price is below even our cautious bear case (73,304 KRW). The market is more pessimistic than our downside scenario.
- The model range is unusually wide (73,304 KRW to 212,571 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 17,745 KRW – 81,475 KRW · fair‑value band 73,304 KRW – 212,571 KRW · the 33,300 KRW price screens below the 98,276 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
T&L Co (340570) currently trades at 33,300 KRW, while our model-based Fair Value estimate is 98,276 KRW, implying the stock looks roughly 195.1% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, T&L Co generated revenue of 158B KRW at a net margin of 24.5%. Revenue declined 12.2% year over year. It earns a return on equity of 20.0%. Fundamentals as of Jul 22, 2026
Our scenario range runs from 73,304 KRW (bear case) to 212,571 KRW (bull case); at 33,300 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 51% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at 195%, 340570 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (163,516 KRW) versus Asset-Based (16,811 KRW). Highest evidence: Growth DCF (80).
Notify me when 340570 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
T&L Co., Ltd. engages in the manufacture and sale of medical and polymer material products in South Korea. Its chemical products include water borne resins, hardeners, functional additives, and urethane foam; wound care products, including hydrocolloid, foam, hydrogel, silicone, alginate, and other products; and orthopedic products, such as cast, splint, …
Full company description
T&L Co., Ltd. engages in the manufacture and sale of medical and polymer material products in South Korea. Its chemical products include water borne resins, hardeners, functional additives, and urethane foam; wound care products, including hydrocolloid, foam, hydrogel, silicone, alginate, and other products; and orthopedic products, such as cast, splint, and other products. T&L Co., Ltd. was founded in 1998 and is headquartered in Yongin-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
T&L Co reported revenue of 164B KRW in FY2025 versus 71.9B KRW in FY2021, a compound +22.9%/yr. Reported net income was 38.1B KRW in FY2025, compounding +18.1%/yr from FY2021.
Watch 340570: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare T&L Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is T&L Co (340570) overvalued or undervalued?
What is the fair value of 340570?
What is the quality score of 340570?
What is the revenue of T&L Co (340570)?
What is the net profit margin of 340570?
Does T&L Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track T&L Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.